Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent # ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
JGO :: Journal of Gynecologic Oncology
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer - ScienceDirect
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Cells | Free Full-Text | Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Table 4 from Surgical management of recurrent ovarian cancer. | Semantic Scholar
Phil Beale highlights the results of DESKTOP3 - ANZGOG
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer | Journal of Clinical Oncology
